Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Genfit    GNFT   FR0004163111

My previous session
Most popular
Real-time Quote. Real-time Tradegate - 01/21 11:35:25 am
17.98 EUR   +0.22%
2018GENFIT SA : half-yearly earnings release
2018GENFIT : Good timing to anticipate the return of volatility
2018GENFIT SA : annual earnings release
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GENFIT : Half-Year Report of Liquidity Contract with CIC

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11/2019 | 06:36am EST

Lille - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announces the half-year report of its liquidity contract with CIC.

Under the liquidity contract granted to CIC by GENFIT, the following resources were in the liquidity account as at December 31, 2018: 27,911 shares

EUR 769,849.43 in cash

At the half-year report as at June 30, 2018, the following resources were available in the liquidity account: 8,693 shares - EUR215,618.25 in cash


GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT's lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide ('RESOLVE-IT') in nonalcoholic steatohepatitis (NASH), considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive results in a Phase 2 clinical trial in Primary Biliary Cholangitis (PBC), a chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111).


This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, including its RESOLVE-IT Phase 3 trial, review and approvals by regulatory authorities, such as the FDA or the EMA, of its drug and diagnostic candidates, the success of any in-licensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed in Section 4 'Main Risks and Uncertainties' of the Company's 2017 Registration Document registered with the French Autorite des Marches Financiers on April 27, 2018 under n-degree R.18-032, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and as updated by the 2018 Half Year Business and Financial Report and available on the Investors page of GENFIT's website. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


Tel: +1 (617) 714 5252

Email: investors@genfit.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GENFIT
11:48aGENFIT : Announces its financial calendar for 2019
01/11GENFIT : Half-Year Report of Liquidity Contract with CIC
01/10GENFIT : Half-year report of liquidity contract with cic
01/04LABORATORY OF AMERICA : GENFIT and LabCorp Sign a Licensing Agreement to Expand ..
01/03GENFIT : and LabCorp Sign a Licensing Agreement to Expand Access to an Innovativ..
2018GENFIT : Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOL..
2018GENFIT : Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOL..
2018GENFIT : Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOL..
2018GENFIT : Positive Phase 2 Results from Study of Elafibranor in Primary Biliary C..
2018FDA NASH guidance charts course for surrogate endpoints tied to biopsies
More news
Financials (€)
Sales 2018 6,91 M
EBIT 2018 -62,9 M
Net income 2018 -67,9 M
Finance 2018 44,5 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 74,5x
EV / Sales 2019 9,72x
Capitalization 559 M
Duration : Period :
Genfit Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENFIT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 8
Average target price 70,9 €
Spread / Average Target 295%
EPS Revisions
Jean-François Mouney Chairman & Chief Executive Officer
Dean W. Hum Deputy CEO, Chief Operating & Scientific Officer
Nathalie Huitorel Chief Financial & Administrative Officer
Florence Séjourné Member-Supervisory Board
Xavier Guille des Buttes Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%22 863
LONZA GROUP8.95%20 746